Module

Cirrhosis and Beyond

Source: Hepatitis Annual Update 2004

Cirrhosis and Beyond


Program Director: John P. Phair, MD

Faculty:

Hugo R. Rosen, MD
  • Hugo R. Rosen, MD

CME CREDIT INFORMATION

Release Date: 09/10/04

Expiration Date: 09/09/05


Physicians: maximum of 0.5 AMA PRA Category 1 Credits™

Status: Please log in to view status

Begin the Module

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Establish prophylactic screening in cirrhotic patients for hepatocellular carcinoma and gastroesophageal varices.

  • Understand the pros and cons of antiviral therapy in cirrhotic patients, including those awaiting liver transplantation.

  • Understand recurrent hepatitis C and the natural history of this disease in the posttransplant recipient.


Content includes:

  • Outcome and Natural History Following Liver Transplantation for Hepatitis C
  • Natural History
  • Treatment of Hepatitis C Recurrence Following Liver Transplantation: When, in Whom, and for How Long?
  • Preemptive Treatment Prior to Liver Transplantation
  • Reversibility of Cirrhosis
  • Screening for Hepatocellular Carcinoma and Gastroesophageal Varices
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.